Desmopressin

Desmopressin
Systematic (IUPAC) name
(2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-
(diaminomethylideneamino)-1-oxopentan-2-yl]-1-
[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-
(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-
6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-
5,8,11,14,17-pentazacycloicosane-4-carbonyl]
pyrrolidine-2-carboxamide
Clinical data
Trade names Ddavp, Minirin, Minirin Melt, Octim, Stimate
AHFS/Drugs.com monograph
Pregnancy
category
  • AU: B2
  • US: B (No risk in non-human studies)
Legal status
Routes of
administration		 IV, IM, SC, intranasal, oral
Pharmacokinetic data
Bioavailability Variable; 0.08–0.16% (oral)
Protein binding 50%
Biological half-life 1.5–2.5 hours
Excretion Renal
Identifiers
CAS Number 16679-58-6 YesY
ATC code H01BA02
PubChem CID 5311065
IUPHAR/BPS 2182
DrugBank DB00035 YesY
ChemSpider 10481973 YesY
UNII ENR1LLB0FP YesY
KEGG D00291 YesY
ChEMBL CHEMBL376685 YesY
Chemical data
Formula C46H64N14O12S2
Molar mass 1069.22 g/mol
  (verify)

Desmopressin (trade names: DDAVP, others) is a synthetic replacement for vasopressin, the hormone that reduces urine production. It may be taken nasally, intravenously, or as an oral or sublingual tablet. Physicians prescribe desmopressin most frequently for treatment of diabetes insipidus, bedwetting, or nocturia.

It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.[1]

Medical uses

Bed wetting

Desmopressin is used to treat nocturnal enuresis (bedwetting). It is usually prescribed in the form of oral desmopressin acetate, DDAVP. Children taking DDAVP have 2.2 fewer wet nights per week and are 4.5 times more likely to sleep without disruption compared with placebo.[2][3]

US drug regulators banned treating nocturnal enuresis with desmopressin nasal sprays after two patients died and fifty-nine other patients suffered seizures. The patients were using desmopressin when they developed hyponatremia, an imbalance of the body's sodium levels.[4]

Nighttime urination

Desmopressin has some benefit in adults who have problems with night time urination (known as nocturia).[5]

Clotting disorders

Desmopressin (DDAVP) stimulates the release of von Willebrand factor (vWF) from the Weibel Palade bodies of endothelial cells, thereby increasing the levels of vWF (as well as coagulant factor VIII) 3 to 5-fold. Desmopressin can be used to promote the release of von Willebrand factor (with subsequent increase in factor VIII survival secondary to vWF complexing) in patients with coagulation disorders such as von Willebrand disease, mild hemophilia A (factor VIII deficiency), and thrombocytopenia. It can be used with uremic induced platelet dysfunction. It is not effective in the treatment of hemophilia B (factor IX deficiency) or severe hemophilia A.

Diabetes insipidus

Desmopressin is used in the treatment of central diabetes insipidus (DI), to replace endogenous antidiuretic hormone (ADH) that is missing in the central nervous system type of this disorder (decreased production of ADH from the posterior pituitary). It is also used in the diagnostic workup for diabetes insipidus, in order to distinguish central from nephrogenic DI.

Side effects

FDA regulators have said that desmopressin tablets can still be considered safe for treatment of nocturnal enuresis as long as the patient is otherwise healthy. Patients must stop taking desmopressin if they develop severe vomiting and diarrhea, fever, the flu, or severe cold. Patients should also be very cautious about taking desmopressin during hot weather conditions or following strenuous exercise, as these conditions can place stress on the body's salt and water balance.

A healthy body needs to maintain a balance of water and salt (sodium). If sodium levels become too low (hyponatremia) – either as a result of increased water take-up or reduced salt levels – a person may have seizures and, in extreme cases, may die.[6]

Mechanism of action

Desmopressin works by limiting the amount of water that is eliminated in the urine. It works at the level of the renal collecting duct by binding to V2 receptors, which signal for the translocation of aquaporin channels via cytosolic vesicles to the apical membrane of the collecting duct. The presence of these aquaporin channels in the distal nephron causes increasing water reabsorption from the urine, which becomes passively re-distributed from the nephron to systemic circulation by way of basolateral membrane channels.[7] Desmopressin also stimulates release of von Willebrand factor from endothelial cells by acting on the V2 receptor.

Desmopressin is degraded more slowly than recombinant vasopressin, and requires less frequent administration. In addition, it has little effect on blood pressure, while vasopressin may cause arterial hypertension. Vasopressin stimulates the release of ACTH, which indirectly increases responsiveness of alpha-1 receptor in blood vessel smooth muscle, increasing vessel tone and blood pressure. Several studies has shown that Desmopressin does not stimulate ACTH release (except in Cushing's Disease),[8][9][10] and therefore does not directly raise blood pressure, however, one study showed that it stimulates ACTH release in over 50% of healthy subjects.[11] Additionally, desmopressin is able to enhance ACTH and cortisol release in normal subjects following oCRH administration, but not in patients with anorexia nervosa.[10]

Chemistry

Desmopressin (1-desamino-8-D-arginine vasopressin) is a man-made form of the normal human hormone arginine vasopressin (the antidiuretic hormone, or ADH), a peptide containing nine amino acids.

Compared to vasopressin, desmopressin's first amino acid has been deaminated, and the arginine at the eighth position is in the dextro rather than the levo form (see stereochemistry).

References

  1. ↑ "19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Retrieved May 10, 2015.
  2. ↑ Evans, JH (2001). "Evidence based management of nocturnal enuresis". BMJ (Clinical research ed.) 323 (7322): 1167–9. doi:10.1136/bmj.323.7322.1167. PMC 1121645. PMID 11711411.
  3. ↑ "La prise en charge de l’énurésie nocturne primaire". Paediatr Child Health 10 (10): 616–620. 2005. PMC 2722621. PMID 19668677.
  4. ↑ 2 Deaths Spur sleep apnea Drug Warning. Webmd.com (2007-12-04). Retrieved on 2011-04-18.
  5. ↑ Ebell, MH; Radke, T; Gardner, J (Sep 2014). "A systematic review of the efficacy and safety of desmopressin for nocturia in adults.". The Journal of Urology 192 (3): 829–35. doi:10.1016/j.juro.2014.03.095. PMID 24704009.
  6. ↑ Archived December 13, 2007 at the Wayback Machine
  7. ↑ Friedman FM, Weiss JP (December 2013). "Desmopressin in the treatment of nocturia: clinical evidence and experience". Ther Adv Urol 5 (6): 310–7. doi:10.1177/1756287213502116. PMC 3825109. PMID 24294289.
  8. ↑ Pecori Giraldi, F; Marini, E; Torchiana, E; Mortini, P; Dubini, A; Cavagnini, F (June 2003). "Corticotrophin-releasing activity of desmopressin in Cushing's disease: lack of correlation between in vivo and in vitro responsiveness.". The Journal of endocrinology 177 (3): 373–9. PMID 12773117.
  9. ↑ Colombo, P; Passini, E; Re, T; Faglia, G; Ambrosi, B (June 1997). "Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess.". Clinical endocrinology 46 (6): 661–8. PMID 9274696.
  10. 1 2 Foppiani, L; Sessarego, P; Valenti, S; Falivene, MR; Cuttica, CM; Giusti Disem, M (October 1996). "Lack of effect of desmopressin on ACTH and cortisol responses to ovine corticotropin-releasing hormone in anorexia nervosa.". European journal of clinical investigation 26 (10): 879–83. PMID 8911861.
  11. ↑ Scott, LV; Medbak, S; Dinan, TG (November 1999). "ACTH and cortisol release following intravenous desmopressin: a dose-response study.". Clinical endocrinology 51 (5): 653–8. PMID 10594528.

Further reading

This article is issued from Wikipedia - version of the Friday, January 29, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.